Market Research Logo

North America Diabetes Drugs Market Forecast 2019-2027

North America Diabetes Drugs Market Forecast 2019-2027
KEY FINDINGS

The expected CAGR of the North American diabetes drugs market over the forecast period of 2019-2027 is 4.98%. The region has the world’s most established market for diabetes drugs and holds more than half of the total market share. The US market holds the maximum share in the sale and distribution of diabetes drugs.

MARKET INSIGHTS

The ageing population in the US has been on the rise since the 1960's. The growing number of people with diabetic conditions acts as a major market driver. Easy accessibility to therapeutic programs and reimbursement options are expected to result in a higher turnout of patients who’re willing to seek treatment. According to forecasts, Canada is supposed to take over the US in terms of market shares by the year 2027.

COMPETITIVE INSIGHTS

Leading brands operating in the North American market for diabetes drugs are Macrogenics, Inc., B.Braun Melsungen Ag, Astrazeneca Plc., Novo Nordisk A/S, Diavacs Inc., Astellas Pharma, Pfizer, Sanofi, Albireo Pharma Inc., Xeris Pharmaceuticals, Glaxosmithkline, Merck And Eli Lilly And Company.


1. Research Scope
1.1. Study Goals
1.2. Scope Of The Market Study
1.3. Who Will Find This Report Useful?
1.4. Study And Forecasting Years
2. Research Methodology
2.1. Sources Of Data
2.1.1. Secondary Data
2.1.2. Primary Data
2.2. Top-down Approach
2.3. Bottom-up Approach
2.4. Data Triangulation
3. Executive Summary
3.1. Market Summary
3.2. Key Findings
3.2.1. Rising Prevalence Of Type 2 Diabetes
3.2.2. Insulin Market Is Anticipated To Generate Highest Revenue
4. Market Determinants
4.1. Market Drivers
4.1.1. Increase In Prevalence Of Diabetes
4.1.2. Advances In Insulin Technology
4.1.3. Growing Elderly Population
4.2. Market Restraints
4.2.1. Stringent Regulatory Conditions And Guidelines For Biosimilar Drugs
4.2.2. Lack Of Awareness Among People
4.2.3. Cost Sensitivity Issues
4.3. Market Opportunities
4.3.1. Development Of New Formulations
4.3.2. Increasing Research And Development
4.4. Market Challenges
4.4.1. Fierce Market Competition
4.4.2. Rising Concerns In Scientific Community
4.4.3. Gaps In National-level Diabetes Management Plans
4.4.4. Poor Storage Conditions And Distribution Policies For Insulin
5. Market Segmentation
5.1. Market By Diabetes Type 2019-2027
5.1.1. Type 1
5.1.2. Type 2
5.2. Market By Product Class 2019-2027
5.2.1. Insulin
5.2.1.1. Fast Acting Insulin
5.2.1.2. Intermediate Acting Insulin
5.2.1.3. Long-acting Insulin
5.2.2. Non-insulin
5.2.2.1. Dpp-4 Inhibitor
5.2.2.2. Glp-1 Receptors Agonists
5.2.2.3. Sglt-2 Inhibitors
5.2.2.4. Other Non-insulin Drugs
6. Key Analytics
6.1. Porter’s Five Force Analysis
6.1.1. Threat Of New Entrants
6.1.2. Threat Of Substitute
6.1.3. Bargaining Power Of Suppliers
6.1.4. Bargaining Power Of Buyers
6.1.5. Threat Of Competitive Rivalry
6.2. Opportunity Matrix
6.3. Etymology Of Diabetes Drugs Market
6.4. Legal, Policy And Regulatory Issues
7. Geographical Analysis
7.1. North America
7.1.1. The United States
7.1.2. Canada
8. Company Profiles
8.1. Eli Lilly And Company
8.1.1. Overview
8.1.2. Products Portfolio
8.1.3. Swot Analysis
8.1.4. Strategic Initiatives
8.2. Astrazeneca Plc.
8.2.1. Overview
8.2.2. Product Portfolio
8.2.3. Swot Analysis
8.2.4. Strategic Initiatives
8.3. B.Braun Melsungen Ag
8.3.1. Overview
8.3.2. Product Portfolio
8.3.3. Scot Analysis
8.3.4. Strategic Analysis
8.4. Novo Nordisk A/S
8.4.1. Overview
8.4.2. Products Portfolio
8.4.3. Swot Analysis
8.4.4. Strategic Initiatives
8.5. Sanofi
8.5.1. Overview
8.5.2. Products Portfolio
8.5.3. Swot Analysis
8.5.4. Strategic Initiatives
8.6. Diavacs Inc.
8.6.1. Overview
8.6.2. Product Portfolio
8.6.3. Swot Analysis
8.7. Xoma Corp.
8.7.1. Overview
8.7.2. Product Portfolio
8.7.3. Swot Analysis
8.7.4. Strategic Initiatives
8.8. Albireo Pharma Inc.
8.8.1. Overview
8.8.2. Product Portfolio
8.8.3. Swot Analysis
8.9. Macrogenics, Inc.
8.9.1. Overview
8.9.2. Product Portfolio
8.9.3. Swot Analysis
8.10. Astellas Pharma
8.10.1. Overview
8.10.2. Product Portfolio
8.10.3. Swot Analysis
8.10.4. Strategic Initiatives
8.11. Glaxosmithkline
8.11.1. Overview
8.11.2. Product Portfolio
8.11.3. Swot Analysis
8.12. Merck
8.12.1. Overview
8.12.2. Product Portfolio
8.12.3. Swot Analysis
8.12.4. Strategic Initiatives
8.13. Pfizer
8.13.1. Overview
8.13.2. Product Portfolio
8.13.3. Swot Analysis
8.13.4. Strategic Initiatives
8.14. Xeris Pharmaceuticals
8.14.1. Overview
8.14.2. Product Portfolio
8.14.3. Swot Analysis
8.14.4. Strategic Initiatives
Table List
Table 1 North America Diabetes Drugs Market 2019-2027 ($ Million)
Table 2 North America Diabetes Drugs Market By Diabetes Types 2019-2027, ($ Million)
Table 3 North America Diabetes Drugs Market In Type 1 Diabetes 2019-2027 ($ Million)
Table 4 North America Diabetes Drugs Market In Type 2 Diabetes 2019-2027 ($ Millions)
Table 5 North America Diabetes Drugs Market By Product Class 2019-2027 ($ Millions)
Table 6 North America Diabetes Drugs Market In Insulin Type 2019-2027 ($ Million)
Table 7 North America Diabetes Drugs Market In Insulin By Types 2019-2027 ($ Million)
Table 8 North America Insulin Market In Fast Acting Insulin 2019-2027 ($ Million)
Table 9 North America Insulin Market In Intermediate Acting Insulin 2019-2027 ($ Million)
Table 10 North America Insulin Market In Long Acting Insulin 2019-2027 ($ Million)
Table 11 North America Diabetes Drugs Market In Non-insulin Drugs 2019-2027 ($ Million)
Table 12 North America Diabetes Drugs Market In Non-insulin Drugs By Types 2019-2027 ($ Million)
Table 13 North America Non-insulin Drugs Market In Dpp-4 Inhibitor 2019-2027 ($ Million)
Table 14 North America Non-insulin Drugs Market In Glp-1 Receptors Agonists 2019-2027 ($ Million)
Table 15 North America Non-insulin Drugs Market In Sglt-2 Inhibitors 2019-2027 ($ Million)
Table 16 North America Non-insulin Drugs Market In Other Non-insulin Drugs 2019-2027 ($ Million)
Table 17 North America Diabetes Drugs Market By Country 2019-2027 ($ Million)
Figures List
Figure 1 North America Diabetes Drugs Market 2019-2027 ($ Billion)
Figure 2 North America Diabetes Drugs Market, By Type 2 Diabetes 2019-2027 ($ Million)
Figure 3 Average Life Expectancy At Birth In 2017, By Gender (In Years)
Figure 4 Porter’s Five Forces Analysis Of Diabetes Drugs Market
Figure 5 The United States Diabetes Drugs Market 2019-2027 ($ Million)
Figure 6 Canada Diabetes Drugs Market 2019-2027 ($ Million)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report